The Scientific Foundation for Personal Genomics: Recommendations from a National Institutes of Health–Centers for Disease Control and Prevention Multidisciplinary Workshop
The Scientific Foundation for Personal Genomics: Recommendations from a National Institutes of Health–Centers for Disease Control and Prevention Multidisciplinary Workshop
Muin J. Khoury, MD, PhD, Colleen M. McBride, PhD, [...], and Jianfeng Xu, MD, DrPH
Abstract
The increasing availability of personal genomic tests has led to discussions about the validity and utility of such tests and the balance of benefits and harms. A multidisciplinary workshop was convened by the National Institutes of Health and the Centers for Disease Control and Prevention to review the scientific foundation for using personal genomics in risk assessment and disease prevention and to develop recommendations for targeted research. The clinical validity and utility of personal genomics is a moving target with rapidly developing discoveries but little translation research to close the gap between discoveries and health impact. Workshop participants made recommendations in five domains: (1) developing and applying scientific standards for assessing personal genomic tests; (2) developing and applying a multidisciplinary research agenda, including observational studies and clinical trials to fill knowledge gaps in clinical validity and utility; (3) enhancing credible knowledge synthesis and information dissemination to clinicians and consumers; (4) linking scientific findings to evidence-based recommendations for use of personal genomics; and (5) assessing how the concept of personal utility can affect health benefits, costs, and risks by developing appropriate metrics for evaluation. To fulfill the promise of personal genomics, a rigorous multidisciplinary research agenda is needed.
Keywords: behavioral sciences, epidemiologic methods, evidence-based medicine, genetics, genetic testing, genomics, medicine, public health
The Scientific Foundation for Personal Genomics: Recommendations from a National Institutes of Health–Centers for Disease Control and Prevention Multidisciplinary Workshop
Muin J Khoury1,2, Colleen M McBride3, Sheri D Schully2, John P A Ioannidis4, W Gregory Feero3, A Cecile J W Janssens5, Marta Gwinn1, Denise G Simons-Morton6, Jay M Bernhardt7, Michele Cargill8, Stephen J Chanock2, George M Church9, Ralph J Coates1, Francis S Collins3, Robert T Croyle2, Barry R Davis10, Gregory J Downing11, Amy DuRoss8, Susan Friedman12, Mitchell H Gail2, Geoffrey S Ginsburg13, Robert C Green14, Mark H Greene2, Philip Greenland15, Jeffrey R Gulcher16, Andro Hsu17, Kathy L Hudson18, Sharon L R Kardia19, Paul L Kimmel20, Michael S Lauer6, Amy M Miller21, Kenneth Offit22, David F Ransohoff23, J Scott Roberts24, Rebekah S Rasooly20, Kari Stefansson16, Sharon F Terry25, Steven M Teutsch26, Angela Trepanier27, Kay L Wanke28, John S Witte29 and Jianfeng Xu30
- 1From the 1Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia
- 2National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- 3National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland
- 4Department of Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece; Tufts University, School of Medicine, Boston, Massachusetts
- 5Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands
- 6National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland
- 7National Center for Health Marketing, Centers for Disease Control and Prevention, Atlanta, Georgia
- 8Navigenics, Redwood Shores, California
- 9Department of Genetics, Harvard Medical School, Boston, Massachusetts
- 10Department of Biostatistics, The University of Texas School of Public Health, Houston, Texas
- 11Personalized Health Care Initiative, United States Department of Health and Human Services, Washington, DC
- 12Facing Our Risk of Cancer Empowered (FORCE), Tampa, Florida
- 13Institute for Genome Sciences and Policy, Center for Genomic Medicine, Duke University, Durham, North Carolina
- 14Departments of Neurology, Medicine (Genetics) and Epidemiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts
- 15Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
- 16deCODE Genetics, Reykjavik, Iceland
- 1723 and Me, Inc. Mountain View, California
- 18Genetics and Public Policy Center, Johns Hopkins University, Washington, DC
- 19Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan
- 20National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
- 21Personalized Medicine Coalition, Washington, DC
- 22Clinical Genetics Service, Memorial Sloan—Kettering Cancer Center, New York, New York
- 23Departments of Medicine, Epidemiology, and Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
- 24Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, Michigan
- 25Genetic Alliance, Washington, DC
- 26Los Angeles County Department of Public Health, Los Angeles, California
- 27Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan
- 28Office of Behavioral and Social Sciences Research, National Institutes of Health, Bethesda, Maryland
- 29Department of Epidemiology and Biostatistics, Institute of Human Genetics, University of California, San Francisco, California
- 30Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Correspondence: Muin J. Khoury, MD, PhD, Office of Public Health Genomics, Centers for Disease Control and Prevention, 1600 Clifton Road, MS E61, Atlanta, GA 30333. E-mail: mkhoury@cdc.gov.
Received 26 March 2009; Accepted 26 March 2009; Published online 16 June 2010.
Disclosure: Several authors have varying conflicts of interest because of employment and other affiliations. See complete list in the Acknowledgments section.
Top
Abstract
The increasing availability of personal genomic tests has led to discussions about the validity and utility of such tests and the balance of benefits and harms. A multidisciplinary workshop was convened by the National Institutes of Health and the Centers for Disease Control and Prevention to review the scientific foundation for using personal genomics in risk assessment and disease prevention and to develop recommendations for targeted research. The clinical validity and utility of personal genomics is a moving target with rapidly developing discoveries but little translation research to close the gap between discoveries and health impact. Workshop participants made recommendations in five domains: (1) developing and applying scientific standards for assessing personal genomic tests; (2) developing and applying a multidisciplinary research agenda, including observational studies and clinical trials to fill knowledge gaps in clinical validity and utility; (3) enhancing credible knowledge synthesis and information dissemination to clinicians and consumers; (4) linking scientific findings to evidence-based recommendations for use of personal genomics; and (5) assessing how the concept of personal utility can affect health benefits, costs, and risks by developing appropriate metrics for evaluation. To fulfill the promise of personal genomics, a rigorous multidisciplinary research agenda is needed.
Keywords:
behavioral sciences; epidemiologic methods; evidence-based medicine; genetics; genetic testing; genomics; medicine; public health
No hay comentarios:
Publicar un comentario